These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 19967537

  • 1. A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.
    Nakachi K, Furuse J, Kinoshita T, Kawashima M, Ishii H, Ikeda M, Mitsunaga S, Shimizu S.
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):527-34. PubMed ID: 19967537
    [Abstract] [Full Text] [Related]

  • 2. S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
    Ke QH, Zhou SQ, Yang JY, Du W, Liang G, Lei Y, Luo F.
    World J Gastroenterol; 2014 Oct 14; 20(38):13987-92. PubMed ID: 25320537
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
    Sudo K, Hara R, Nakamura K, Kita E, Tsujimoto A, Yamaguchi T.
    Cancer Chemother Pharmacol; 2017 Jul 14; 80(1):195-202. PubMed ID: 28597040
    [Abstract] [Full Text] [Related]

  • 4. A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
    Oh DY, Cha Y, Choi IS, Yoon SY, Choi IK, Kim JH, Oh SC, Kim CD, Kim JS, Bang YJ, Kim YH.
    Cancer Chemother Pharmacol; 2010 Feb 14; 65(3):527-36. PubMed ID: 19578850
    [Abstract] [Full Text] [Related]

  • 5. Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer.
    Kurt E, Kurt M, Kanat O, Cetintas SK, Aygun S, Palazoglu T, Ozkan L, Evrensel T, Kaya E, Manavoglu O.
    Tumori; 2006 Feb 14; 92(6):481-6. PubMed ID: 17260487
    [Abstract] [Full Text] [Related]

  • 6. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA, Lacy J, Portales F, Sobrero A, Pazo-Cid R, Manzano Mozo JL, Kim EJ, Dowden S, Zakari A, Borg C, Terrebonne E, Rivera F, Sastre J, Bathini V, López-Trabada D, Asselah J, Saif MW, Shiansong Li J, Ong TJ, Nydam T, Hammel P.
    Lancet Gastroenterol Hepatol; 2020 Mar 14; 5(3):285-294. PubMed ID: 31953079
    [Abstract] [Full Text] [Related]

  • 7. Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
    Kim JS, Lim JH, Kim JH, Im SA, Chie EK, Hwang JH, Kim TY, Bang YJ, Ha SW, Yoon YB.
    Cancer Chemother Pharmacol; 2012 Sep 14; 70(3):381-9. PubMed ID: 22806305
    [Abstract] [Full Text] [Related]

  • 8. Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.
    Song H, Han B, Park CK, Kim JH, Jeon JY, Kim IG, Kim HJ, Jung JY, Kim JH, Kwon JH, Jang G, Kim HY, Kim HS, Choi DR, Zang DY.
    Cancer Chemother Pharmacol; 2013 Oct 14; 72(4):845-52. PubMed ID: 23978987
    [Abstract] [Full Text] [Related]

  • 9. Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study.
    Woo SM, Kim MK, Joo J, Yoon KA, Park B, Park SJ, Han SS, Lee JH, Hong EK, Kim YH, Moon H, Kong SY, Kim TH, Lee WJ.
    Cancer Res Treat; 2017 Oct 14; 49(4):1022-1032. PubMed ID: 28111423
    [Abstract] [Full Text] [Related]

  • 10. Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
    Ueno H, Okusaka T, Furuse J, Yamao K, Funakoshi A, Boku N, Ohkawa S, Yokosuka O, Tanaka K, Moriyasu F, Nakamori S, Sato T.
    Jpn J Clin Oncol; 2011 Aug 14; 41(8):953-8. PubMed ID: 21715364
    [Abstract] [Full Text] [Related]

  • 11. Retrospective study of gemcitabine plus S-1 versus gemcitabine alone in cases with unresectable advanced pancreatic cancer.
    Suzuki S, Ozaki Y, Saida S, Kaji S, Koike N, Harada N, Hayashi T, Suzuki M.
    Hepatogastroenterology; 2013 Jun 14; 60(124):916-20. PubMed ID: 23478143
    [Abstract] [Full Text] [Related]

  • 12. Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
    Cao C, Kuang M, Xu W, Zhang X, Chen J, Tang C.
    Jpn J Clin Oncol; 2015 Dec 14; 45(12):1122-30. PubMed ID: 26518328
    [Abstract] [Full Text] [Related]

  • 13. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V, Siveke JT, Algül H, Goekkurt E, Siegler G, Martens U, Waldschmidt D, Pelzer U, Fuchs M, Kullmann F, Boeck S, Ettrich TJ, Held S, Keller R, Klein I, Germer CT, Stein H, Friess H, Bahra M, Jakobs R, Hartlapp I, Heinemann V, German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigators.
    Lancet Gastroenterol Hepatol; 2021 Feb 14; 6(2):128-138. PubMed ID: 33338442
    [Abstract] [Full Text] [Related]

  • 14. A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
    Arima S, Shimizu K, Okamoto T, Toki M, Suzuki Y, Okano N, Naruge D, Kawai K, Kobayashi T, Kasuga A, Kitamura H, Takasu A, Nagashima F, Sugiyama M, Furuse J.
    Anticancer Res; 2017 Feb 14; 37(2):909-914. PubMed ID: 28179351
    [Abstract] [Full Text] [Related]

  • 15. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
    Saito K, Isayama H, Nakai Y, Takahara N, Ishigaki K, Takeda T, Hakuta R, Saito T, Uchino R, Kishikawa T, Hamada T, Mizuno S, Sasaki T, Kogure H, Matsubara S, Yamamoto N, Ijichi H, Tateishi K, Tada M, Koike K.
    Invest New Drugs; 2019 Apr 14; 37(2):338-344. PubMed ID: 30411217
    [Abstract] [Full Text] [Related]

  • 16. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    Badiyan SN, Olsen JR, Lee AY, Yano M, Menias CO, Khwaja S, Wang-Gillam A, Strasberg SM, Hawkins WG, Linehan DC, Myerson RJ, Parikh PJ.
    Am J Clin Oncol; 2016 Feb 14; 39(1):1-7. PubMed ID: 26132367
    [Abstract] [Full Text] [Related]

  • 17. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer.
    Lee KH, Chie EK, Im SA, Kim JH, Kwon J, Han SW, Oh DY, Jang JY, Kim JS, Kim TY, Bang YJ, Kim SW, Ha SW.
    Cancer Res Treat; 2021 Oct 14; 53(4):1096-1103. PubMed ID: 33421976
    [Abstract] [Full Text] [Related]

  • 18. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
    Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, Morinaga S, Kainuma O, Imai K, Sata N, Hishinuma S, Ojima H, Yamaguchi R, Hirano S, Sudo T, Ohashi Y, JASPAC 01 Study Group.
    Lancet; 2016 Jul 16; 388(10041):248-57. PubMed ID: 27265347
    [Abstract] [Full Text] [Related]

  • 19. A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
    Kobayashi S, Honda G, Kurata M, Okuda Y, Sakamoto K, Karasawa K, Chang T, Egawa N, Kamisawa T, Omuro Y, Tsuruta K.
    Hepatogastroenterology; 2015 Jun 16; 62(140):1031-6. PubMed ID: 26902051
    [Abstract] [Full Text] [Related]

  • 20. Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers.
    Maemura K, Mataki Y, Kurahara H, Kawasaki Y, Iino S, Sakoda M, Uchikado Y, Arigami T, Uenosono Y, Mori S, Ueno S, Shinchi H, Natsugoe S.
    Anticancer Res; 2017 Jan 16; 37(1):233-237. PubMed ID: 28011497
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.